Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing @entity2449 and/or @entity4136 treatment in @entity1 with XXXX 2 @entity6 .

@entity1 @entity390 @entity6 @entity9208 @entity164 @entity4136 @entity42652 @entity413 @entity2449
OBJECTIVE: @entity42652 (synthetic exendin-4; exenatide) is a peptide that enhances @entity413 -dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. @entity42652 also promotes beta-cell proliferation and neogenesis in vitro and in animal models. This study examines the activity and safety of subcutaneously injected @entity42652 in @entity1 with @entity164 2 @entity6 currently treated with diet and/or oral antidiabetic agents (OAAs). RESEARCH DESIGN AND METHODS: A total of 109 @entity1 treated with diet and a @entity4136 and/or @entity2449 were enrolled in a blinded study. @entity1 were randomly assigned to one of three subcutaneously (SC) injected regimens of @entity42652 (0.08 micro g/kg) or placebo for 28 days. RESULTS: All three @entity42652 regimens led to significant reductions in serum @entity9208 relative to placebo (P <or= 0.004). Mean reductions ranged from 39 to 46 micro mol/l. All @entity42652 groups had reductions in HbA(1c) ranging from 0.7 to 1.1% (P <or= 0.006). An end-of-study HbA(1c) <7% was achieved by 15% of @entity42652 @entity1 versus 4% of placebo @entity1 , confirming @entity42652 effects on fasting and postprandial glycemia. On days 14 and 28, the beta-cell index (homeostasis model assessment) for @entity1 treated with @entity42652 was 50-100% higher than baseline, contrasting with unchanged levels for placebo. The most common adverse event was transient mild-to-moderate @entity390 . CONCLUSIONS: @entity42652 is a promising therapeutic for @entity1 with @entity164 2 @entity6 . In this study, it had significant effects on HbA(1c) levels in @entity1 not currently achieving optimal @entity413 control with diet and/or OAAs.
